7 results about "Antiangiogenic agents" patented technology

The present disclosure relates to a mixed antibody comprising anti-CTLA4 and anti-PD1, or a use of the mixed antibody in combination with a chemotherapeutic drug and / or an anti-angiogenic agent in the treatment of hepatocellular carcinoma.

The present disclosure provides methods of treating hepatocellular carcinoma with a combination of a LAG-3 antagonist, a PD-1 pathway inhibitor, and an anti-angiogenic agent.

Provided is an antiangiogenic agent in the form of a vehicle, e.g., a nanoparticle associated (directly or indirectly) with at least one ocular angiogenesis growth factor aptamer, wherein said association labile to interaction between the aptamer and an ocular angiogenesis growth factor.

Anti-angiogenic agents or polypeptides have an amino acid segment substantially similar to domain one of CD2. The polypeptide has a β-sheet formed by two segments. Methods of using such agents and polypeptide are also included.

The antiangiogenic agent or polypeptide has an amino acid segment substantially similar to domain 1 of CD2. The polypeptide has a β-sheet formed by the two segments. Methods of using such agents and polypeptides are also included. The agent or polypeptide has a terminal glycine.

Administration of a hypoxia activated prodrug in combination with an antiangiogenic agent is useful for treating cancer.

The present invention belongs to the field of biomedicine technology, and specifically relates to the use of OX40 activating antibodies and anti-angiogenic agents in the preparation of anti-tumor drugs. The OX40 activating antibody is OX86, and the anti-angiogenic agent is verteporfin. OX40 causes an "anti-tumor" effect in T cells and induces a "pro-tumor" effect in endothelial cells. Therefore, the OX40 activating antibody and the anti-angiogenic agent are used in combination, and while activating the OX40 "anti-tumor" signal in T cells, the anti-angiogenic agent is used to block the "pro-tumor" effect of the OX40 activating antibody in endothelial cells. The two components act synergistically, showing a better tumor inhibition effect than the combined treatment of OX40 activating antibody and PD-1 monoclonal antibody (CD279).